Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-MS adaptive phase 3 trial of anti-EBV therapy in progressive multiple sclerosis
ACTRN12623000849695Phase 3Not yet recruiting
- Sponsor
- Griffith University
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of spironolactone and famciclovir in multiple sclerosis (MS), sponsored by Griffith University. Primary endpoints: Stage 1 co-primary endpoint: salivary EBV DNA detection frequency, Stage 1 co-primary endpoint: serum EBNA1 antibody titre and 1 more. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
spironolactonefamciclovir
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ACTRN12623000849695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000849695.